Gyre Therapeutics Inc. (GYRE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $471.74M
Last updated: Nov 17, 2026 at 11:05 AM ET
Gyre Therapeutics Inc. (GYRE) Financials: Revenue, Profit and Cash Flow
Gyre Therapeutics reported revenue of $116.59M for the fiscal year ended Dec 31, 2025, up 10.2% from the year before. That year, net income was $9.88M with a net margin of 8.5%, operating cash flow was $1.01M and free cash flow was -$180.00K. The quarter ended Sep 30, 2026 had revenue of $32.93M and net income of -$2.48M.
Revenue and Margins
The operating margin was 9.9% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $399.00K, a compound annual rate of 87.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $116.59M | +10.2% | 95.4% | 9.9% | 8.5% |
| Dec 2024 | $105.76M | -6.8% | 96.3% | 15.3% | 16.9% |
| Dec 2023 | $113.45M | +10.9% | 95.9% | -59.3% | -75.3% |
| Dec 2022 | $102.29M | +1294.0% | 95.3% | 9.0% | 4.2% |
| Dec 2021 | $7.34M | -65.0% | -0.6% | -1197.8% | -1198.3% |
| Dec 2020 | $20.95M | N/A | 56.3% | -273.9% | -268.5% |
| Dec 2019 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2018 | $6.00K | -99.4% | 100.0% | -563700.0% | -500916.7% |
| Dec 2017 | $1.02M | +155.1% | 100.0% | -2143.6% | -2118.0% |
| Dec 2016 | $399.00K | N/A | 100.0% | -5117.3% | -4246.9% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 44.8% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $116.59M | $105.76M | $113.45M | $102.29M | $7.34M | $20.95M | $0 | $6.00K | $1.02M | $399.00K |
| Cost of revenue | $5.42M | $3.88M | $4.64M | $4.79M | $7.38M | $9.16M | $0 | $0 | $0 | $0 |
| Gross profit | $111.17M | $101.87M | $108.81M | $97.50M | -$42.00K | $11.79M | $0 | $6.00K | $1.02M | $399.00K |
| Research and development | $13.70M | $12.02M | $96.88M | $16.69M | $68.89M | $52.98M | $43.86M | $21.47M | $12.85M | $11.55M |
| Operating income | $11.49M | $16.16M | -$67.23M | $9.20M | -$87.89M | -$57.37M | -$57.28M | -$33.82M | -$21.82M | -$20.42M |
| Net income | $9.88M | $17.90M | -$85.48M | $4.31M | -$87.93M | -$56.24M | -$55.18M | -$30.05M | -$21.56M | -$16.95M |
| EBITDA | $15.21M | $23.26M | N/A | $9.81M | -$87.60M | -$57.23M | -$57.13M | -$33.67M | -$21.65M | -$20.03M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.93M | $29.11M | $22.52M | $37.20M | $32.69M | $29.73M | $22.06M | $27.87M | $25.49M | $25.23M | $27.17M | $27.15M |
| Gross profit | $30.99M | $26.90M | $21.29M | $35.45M | $31.07M | $28.58M | $21.16M | $26.70M | $24.53M | $24.45M | $26.19M | $25.90M |
| Operating income | -$1.52M | -$14.36M | -$9.36M | $118.00K | $1.49M | -$2.24M | $2.27M | $665.00K | $4.23M | $3.19M | $8.07M | -$91.63M |
| Net income | -$2.48M | -$14.27M | -$9.86M | -$1.37M | $1.93M | -$2.24M | $3.73M | $569.00K | $2.86M | $4.54M | $9.94M | -$100.98M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $636.00K by $48.56M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $219.76M | $125.41M | $116.54M | $84.75M | $55.66M | $94.85M | $98.55M | $124.92M | $39.51M | $38.09M |
| Current assets | $149.36M | $64.79M | $57.22M | $49.65M | $51.48M | $89.51M | $96.07M | $123.99M | $39.11M | $37.52M |
| Cash and equivalents | $49.19M | $11.81M | $33.51M | $25.18M | $44.35M | $30.36M | $15.37M | $31.21M | $14.47M | $10.26M |
| Total liabilities | $31.40M | $27.00M | $38.06M | $12.54M | $14.57M | $18.78M | $30.22M | $4.97M | $8.74M | $22.02M |
| Short-term debt | $636.00K | $713.00K | $210.00K | $492.00K | $1.98M | $663.00K | $483.00K | N/A | $5.08M | $19.40M |
| Shareholder equity | $62.50M | $63.32M | -$15.83M | $42.52M | $41.09M | $76.07M | $68.34M | $119.94M | $30.77M | $16.07M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $201.25M | $199.25M | $162.01M | $166.13M | $159.38M | $152.65M | $129.79M | $125.41M | $125.24M | $120.93M | $122.01M | $116.54M |
| Total liabilities | $35.18M | $34.34M | $25.03M | $23.85M | $21.97M | $23.20M | $25.49M | $27.00M | $26.77M | $27.58M | $33.24M | $102.59M |
| Cash and equivalents | $41.64M | $43.29M | $37.50M | $37.07M | $40.40M | $36.49M | $15.04M | $11.81M | $15.87M | $16.10M | $29.79M | $33.51M |
| Shareholder equity | $107.95M | $107.93M | $101.31M | $106.03M | $101.92M | $92.03M | $68.12M | $63.32M | $63.18M | $60.35M | $56.64M | -$15.83M |
Cash Flow
In the fiscal year ended Dec 2025, capital expenditures exceeded operating cash flow, leaving negative free cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.01M | -$3.64M | $25.89M | $10.68M | -$83.75M | -$55.05M | -$43.61M | -$28.55M | -$19.94M | -$18.47M |
| Capital expenditures | $1.19M | $2.31M | $8.52M | $4.99M | $839.00K | $267.00K | $64.00K | $376.00K | $23.00K | $468.00K |
| Free cash flow | -$180.00K | -$5.96M | $17.38M | $5.69M | -$84.59M | -$55.31M | -$43.68M | -$28.93M | -$19.96M | -$18.94M |
| Dividends paid | N/A | N/A | N/A | $45.03M | $0 | N/A | N/A | N/A | $3.95M | N/A |
| Investing cash flow | -$474.00K | -$19.88M | -$19.76M | -$13.81M | $48.19M | $9.66M | $27.39M | -$71.32M | -$11.20M | -$1.31M |
| Financing cash flow | $24.38M | $2.10M | $2.50M | $0 | $49.55M | $60.38M | $327.00K | $111.33M | $21.08M | $948.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.98M | -$16.73M | $3.18M | -$5.63M | -$2.58M | -$7.47M | -$129.00K | -$2.76M | $1.73M | -$5.49M | $2.88M | $3.36M |
| Capital expenditures | $979.00K | $262.00K | $178.00K | $144.00K | $740.00K | $335.00K | $122.00K | $65.00K | $693.00K | $1.46M | $231.00K | $2.32M |
| Free cash flow | -$4.96M | -$16.99M | $3.00M | -$5.77M | -$3.32M | -$7.81M | -$251.00K | -$2.82M | $1.03M | -$6.95M | $2.65M | $1.04M |
Frequently Asked Questions About GYRE
What is Gyre Therapeutics' annual revenue?
Gyre Therapeutics reported revenue of $116.59M for the fiscal year ended Dec 31, 2025.
How fast is Gyre Therapeutics' revenue growing?
Revenue was up 10.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 4.5%.
Is Gyre Therapeutics profitable?
Yes. Gyre Therapeutics reported net income of $9.88M for the fiscal year ended Dec 31, 2025, with a net margin of 8.5%.
How much free cash flow does GYRE generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.01M minus capital expenditures of $1.19M produced free cash flow of -$180.00K.
How much debt does Gyre Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $636.00K and cash and equivalents of $49.19M.
GYRE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors